Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-02-09

AUTHORS

Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki, Tatsuki Teranishi

ABSTRACT

IntroductionTeneligliptin/canagliflozin combination tablets, which combine a dipeptidyl peptidase-4 (DPP-4) inhibitor (teneligliptin) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin), are a treatment option for type 2 diabetes mellitus (T2DM) in Japan. This post-marketing surveillance evaluated the real-world safety and effectiveness of teneligliptin/canagliflozin combination tablets, and changes in self-reported adherence to oral antihyperglycaemic agents.MethodsJapanese patients with T2DM who were prescribed the combination tablets for the first time between December 2017 and June 2018 were registered and followed up for 12 months. Safety and effectiveness were assessed in terms of adverse drug reactions (ADRs) and the changes in haemoglobin A1c (HbA1c) and body weight from baseline to 12 months with the last observation carried forward, respectively. Adherence was assessed using the Morisky Medication Adherence Scale 8.ResultsOverall, 821 patients were eligible for the analyses, including 733 who were prescribed the combination tablets for 12 months. ADRs and serious ADRs were reported in 4.38% and 0.85% of patients, respectively. Gastrointestinal disorders (0.97%) were the most common class of ADRs. No new safety concerns were identified beyond those described in the Japanese package insert. The changes in HbA1c and body weight from baseline to 12 months were − 0.43 ± 0.93% and − 1.29 ± 5.57 kg, respectively. The reductions in HbA1c at 12 months tended to be greater among patients who switched from either DPP-4 inhibitors (− 0.71 ± 0.89%) or SGLT2 inhibitors (− 0.51 ± 1.00%) relative to patients who switched from both (− 0.22 ± 0.88%). The decrease in body weight was greatest among patients who switched from DPP-4 inhibitors. An improvement in self-reported adherence to oral antihyperglycaemic agents occurred after switching to the combination tablets.ConclusionTeneligliptin/canagliflozin combination tablets were effective and associated with an improvement in adherence without new safety concerns in Japanese patients with T2DM in real-world clinical practice.Trial RegistrationJapicCTI-173778. More... »

PAGES

1642-1658

References to SciGraph publications

  • 2021-12-02. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance in ADVANCES IN THERAPY
  • 2018-07-13. Guidelines for clinical evaluation of chronic kidney disease in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 2021-06-17. Variables associated with adherence to the treatment of type 2 diabetes mellitus among elderly people in DIABETOLOGY INTERNATIONAL
  • 2019-04-13. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice in DRUGS
  • 2014-05-08. Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes in INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
  • 2002-04-30. The Relative Importance of Physician Communication, Participatory Decision Making, and Patient Understanding in Diabetes Self‐management in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2019-03-08. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes in DIABETES THERAPY
  • 2019-12-23. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan in ADVANCES IN THERAPY
  • 2015-05-06. β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians in CURRENT DIABETES REPORTS
  • 2020-09-14. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus in NATURE REVIEWS ENDOCRINOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12325-021-02038-5

    DOI

    http://dx.doi.org/10.1007/s12325-021-02038-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1145402123

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35138572


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Glucose", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Body Weight", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Canagliflozin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dipeptidyl-Peptidase IV Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glycated Hemoglobin A", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypoglycemic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Japan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Product Surveillance, Postmarketing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thiazolidines", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Toranomon Hospital, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410813.f", 
              "name": [
                "Toranomon Hospital, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kadowaki", 
            "givenName": "Takashi", 
            "id": "sg:person.01353472360.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353472360.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.258799.8", 
              "name": [
                "Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Inagaki", 
            "givenName": "Nobuya", 
            "id": "sg:person.01254012666.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254012666.61"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.258269.2", 
              "name": [
                "Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Watada", 
            "givenName": "Hirotaka", 
            "id": "sg:person.01004741716.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004741716.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-ku, 541-8505, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418306.8", 
              "name": [
                "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-ku, 541-8505, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sasaki", 
            "givenName": "Kazuyo", 
            "id": "sg:person.01335361505.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335361505.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418306.8", 
              "name": [
                "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mori-Anai", 
            "givenName": "Kazumi", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418306.8", 
              "name": [
                "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iwasaki", 
            "givenName": "Tomohisa", 
            "id": "sg:person.013066600563.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013066600563.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Quality and Vigilance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418306.8", 
              "name": [
                "Quality and Vigilance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Teranishi", 
            "givenName": "Tatsuki", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s13300-019-0590-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1112634529", 
              "https://doi.org/10.1007/s13300-019-0590-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11096-014-9938-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013313922", 
              "https://doi.org/10.1007/s11096-014-9938-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41574-020-0399-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1130824579", 
              "https://doi.org/10.1038/s41574-020-0399-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40265-019-01086-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113462075", 
              "https://doi.org/10.1007/s40265-019-01086-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12325-019-01189-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123606886", 
              "https://doi.org/10.1007/s12325-019-01189-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12325-021-01984-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1143544089", 
              "https://doi.org/10.1007/s12325-021-01984-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1046/j.1525-1497.2002.10905.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019640859", 
              "https://doi.org/10.1046/j.1525-1497.2002.10905.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13340-021-00518-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138951105", 
              "https://doi.org/10.1007/s13340-021-00518-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11892-015-0602-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026921846", 
              "https://doi.org/10.1007/s11892-015-0602-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10157-018-1615-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1105570813", 
              "https://doi.org/10.1007/s10157-018-1615-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-02-09", 
        "datePublishedReg": "2022-02-09", 
        "description": "IntroductionTeneligliptin/canagliflozin combination tablets, which combine a dipeptidyl peptidase-4 (DPP-4) inhibitor (teneligliptin) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin), are a treatment option for type 2 diabetes mellitus (T2DM) in Japan. This post-marketing surveillance evaluated the real-world safety and effectiveness of teneligliptin/canagliflozin combination tablets, and changes in self-reported adherence to oral antihyperglycaemic agents.MethodsJapanese patients with T2DM who were prescribed the combination tablets for the first time between December 2017 and June 2018 were registered and followed up for 12\u00a0months. Safety and effectiveness were assessed in terms of adverse drug reactions (ADRs) and the changes in haemoglobin A1c (HbA1c) and body weight from baseline to 12\u00a0months with the last observation carried forward, respectively. Adherence was assessed using the Morisky Medication Adherence Scale 8.ResultsOverall, 821 patients were eligible for the analyses, including 733 who were prescribed the combination tablets for 12\u00a0months. ADRs and serious ADRs were reported in 4.38% and 0.85% of patients, respectively. Gastrointestinal disorders (0.97%) were the most common class of ADRs. No new safety concerns were identified beyond those described in the Japanese package insert. The changes in HbA1c and body weight from baseline to 12\u00a0months were \u2212\u00a00.43\u00a0\u00b1\u00a00.93% and \u2212\u00a01.29\u00a0\u00b1\u00a05.57\u00a0kg, respectively. The reductions in HbA1c at 12\u00a0months tended to be greater among patients who switched from either DPP-4 inhibitors (\u2212\u00a00.71\u00a0\u00b1\u00a00.89%) or SGLT2 inhibitors (\u2212\u00a00.51\u00a0\u00b1\u00a01.00%) relative to patients who switched from both (\u2212\u00a00.22\u00a0\u00b1\u00a00.88%). The decrease in body weight was greatest among patients who switched from DPP-4 inhibitors. An improvement in self-reported adherence to oral antihyperglycaemic agents occurred after switching to the combination tablets.ConclusionTeneligliptin/canagliflozin combination tablets were effective and associated with an improvement in adherence without new safety concerns in Japanese patients with T2DM in real-world clinical practice.Trial RegistrationJapicCTI-173778.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12325-021-02038-5", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096634", 
            "issn": [
              "0741-238X", 
              "1865-8652"
            ], 
            "name": "Advances in Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "39"
          }
        ], 
        "keywords": [
          "adverse drug reactions", 
          "oral antihyperglycaemic agents", 
          "self-reported adherence", 
          "DPP-4 inhibitors", 
          "new safety concerns", 
          "combination tablet", 
          "body weight", 
          "antihyperglycaemic agents", 
          "sodium-glucose cotransporter 2 inhibitors", 
          "dipeptidyl peptidase-4 inhibitors", 
          "type 2 diabetes mellitus", 
          "real-world clinical practice", 
          "serious adverse drug reactions", 
          "cotransporter 2 inhibitors", 
          "peptidase-4 inhibitors", 
          "real-world safety", 
          "Japanese package inserts", 
          "post-marketing surveillance", 
          "real-world evidence", 
          "safety concerns", 
          "MethodsJapanese patients", 
          "diabetes mellitus", 
          "SGLT2 inhibitors", 
          "gastrointestinal disorders", 
          "treatment options", 
          "drug reactions", 
          "Japanese patients", 
          "patients", 
          "package inserts", 
          "clinical practice", 
          "type 2", 
          "marketing surveillance", 
          "months", 
          "adherence", 
          "mellitus", 
          "T2DM", 
          "last observation", 
          "inhibitors", 
          "baseline", 
          "surveillance", 
          "safety", 
          "tablets", 
          "HbA1c", 
          "agents", 
          "weight", 
          "hemoglobin", 
          "disorders", 
          "treatment", 
          "common class", 
          "changes", 
          "improvement", 
          "options", 
          "evidence", 
          "concern", 
          "decrease", 
          "effectiveness", 
          "Japan", 
          "reduction", 
          "first time", 
          "practice", 
          "time", 
          "analysis", 
          "inserts", 
          "observations", 
          "reaction", 
          "terms", 
          "class"
        ], 
        "name": "Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan", 
        "pagination": "1642-1658", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1145402123"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12325-021-02038-5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35138572"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12325-021-02038-5", 
          "https://app.dimensions.ai/details/publication/pub.1145402123"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_943.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12325-021-02038-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-021-02038-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-021-02038-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-021-02038-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-021-02038-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    269 TRIPLES      21 PREDICATES      114 URIs      96 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12325-021-02038-5 schema:about N1f670cf5912b4e5396b3df2def60c4af
    2 N241579e5d8bd401a9c24e3576d0262f4
    3 N3c956f93b5744a6da73dae4673f8435d
    4 N619790f77a6e49b58c87d08d57611715
    5 N6aac6b88935642eca330abd6d004e42a
    6 N9b1236aa22754913ba4a8e471e72eead
    7 N9bdf923e83c14108aaa9fcb9c0111b9d
    8 Na21114c514e549fda67bcd30250addbe
    9 Na5a70a76cb8d47f48a459041e8ea181e
    10 Nbfe09c58865243b59c5ebbe3f1d2f586
    11 Nd2a275f05e2442baa7ecf884c23609dd
    12 Ndedab7c1275b46f1b10b0ac4709db215
    13 anzsrc-for:11
    14 anzsrc-for:1103
    15 schema:author N55a0957764164c7281164e52c27244c5
    16 schema:citation sg:pub.10.1007/s10157-018-1615-x
    17 sg:pub.10.1007/s11096-014-9938-5
    18 sg:pub.10.1007/s11892-015-0602-9
    19 sg:pub.10.1007/s12325-019-01189-w
    20 sg:pub.10.1007/s12325-021-01984-4
    21 sg:pub.10.1007/s13300-019-0590-x
    22 sg:pub.10.1007/s13340-021-00518-1
    23 sg:pub.10.1007/s40265-019-01086-0
    24 sg:pub.10.1038/s41574-020-0399-8
    25 sg:pub.10.1046/j.1525-1497.2002.10905.x
    26 schema:datePublished 2022-02-09
    27 schema:datePublishedReg 2022-02-09
    28 schema:description IntroductionTeneligliptin/canagliflozin combination tablets, which combine a dipeptidyl peptidase-4 (DPP-4) inhibitor (teneligliptin) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin), are a treatment option for type 2 diabetes mellitus (T2DM) in Japan. This post-marketing surveillance evaluated the real-world safety and effectiveness of teneligliptin/canagliflozin combination tablets, and changes in self-reported adherence to oral antihyperglycaemic agents.MethodsJapanese patients with T2DM who were prescribed the combination tablets for the first time between December 2017 and June 2018 were registered and followed up for 12 months. Safety and effectiveness were assessed in terms of adverse drug reactions (ADRs) and the changes in haemoglobin A1c (HbA1c) and body weight from baseline to 12 months with the last observation carried forward, respectively. Adherence was assessed using the Morisky Medication Adherence Scale 8.ResultsOverall, 821 patients were eligible for the analyses, including 733 who were prescribed the combination tablets for 12 months. ADRs and serious ADRs were reported in 4.38% and 0.85% of patients, respectively. Gastrointestinal disorders (0.97%) were the most common class of ADRs. No new safety concerns were identified beyond those described in the Japanese package insert. The changes in HbA1c and body weight from baseline to 12 months were − 0.43 ± 0.93% and − 1.29 ± 5.57 kg, respectively. The reductions in HbA1c at 12 months tended to be greater among patients who switched from either DPP-4 inhibitors (− 0.71 ± 0.89%) or SGLT2 inhibitors (− 0.51 ± 1.00%) relative to patients who switched from both (− 0.22 ± 0.88%). The decrease in body weight was greatest among patients who switched from DPP-4 inhibitors. An improvement in self-reported adherence to oral antihyperglycaemic agents occurred after switching to the combination tablets.ConclusionTeneligliptin/canagliflozin combination tablets were effective and associated with an improvement in adherence without new safety concerns in Japanese patients with T2DM in real-world clinical practice.Trial RegistrationJapicCTI-173778.
    29 schema:genre article
    30 schema:isAccessibleForFree true
    31 schema:isPartOf N0756c2a26d3b437394b3d8c594f538f5
    32 N58c42452a63c4d258addea1fe63baf19
    33 sg:journal.1096634
    34 schema:keywords DPP-4 inhibitors
    35 HbA1c
    36 Japan
    37 Japanese package inserts
    38 Japanese patients
    39 MethodsJapanese patients
    40 SGLT2 inhibitors
    41 T2DM
    42 adherence
    43 adverse drug reactions
    44 agents
    45 analysis
    46 antihyperglycaemic agents
    47 baseline
    48 body weight
    49 changes
    50 class
    51 clinical practice
    52 combination tablet
    53 common class
    54 concern
    55 cotransporter 2 inhibitors
    56 decrease
    57 diabetes mellitus
    58 dipeptidyl peptidase-4 inhibitors
    59 disorders
    60 drug reactions
    61 effectiveness
    62 evidence
    63 first time
    64 gastrointestinal disorders
    65 hemoglobin
    66 improvement
    67 inhibitors
    68 inserts
    69 last observation
    70 marketing surveillance
    71 mellitus
    72 months
    73 new safety concerns
    74 observations
    75 options
    76 oral antihyperglycaemic agents
    77 package inserts
    78 patients
    79 peptidase-4 inhibitors
    80 post-marketing surveillance
    81 practice
    82 reaction
    83 real-world clinical practice
    84 real-world evidence
    85 real-world safety
    86 reduction
    87 safety
    88 safety concerns
    89 self-reported adherence
    90 serious adverse drug reactions
    91 sodium-glucose cotransporter 2 inhibitors
    92 surveillance
    93 tablets
    94 terms
    95 time
    96 treatment
    97 treatment options
    98 type 2
    99 type 2 diabetes mellitus
    100 weight
    101 schema:name Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
    102 schema:pagination 1642-1658
    103 schema:productId N3449d035938e43159a64c2d2cfe79efc
    104 N54f0866afdfb4e47995de2d51e0a727f
    105 Nff2f7084b98d4bada87c22669dedd38c
    106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145402123
    107 https://doi.org/10.1007/s12325-021-02038-5
    108 schema:sdDatePublished 2022-10-01T06:50
    109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    110 schema:sdPublisher N3c33aeb77e5f4f17b3bd042a95571d2e
    111 schema:url https://doi.org/10.1007/s12325-021-02038-5
    112 sgo:license sg:explorer/license/
    113 sgo:sdDataset articles
    114 rdf:type schema:ScholarlyArticle
    115 N0756c2a26d3b437394b3d8c594f538f5 schema:issueNumber 4
    116 rdf:type schema:PublicationIssue
    117 N098202a1ab5f43d4a45df8eb451feb8f schema:affiliation grid-institutes:grid.418306.8
    118 schema:familyName Teranishi
    119 schema:givenName Tatsuki
    120 rdf:type schema:Person
    121 N1cefa83b97eb4b7681f0f66e9bdf6a97 schema:affiliation grid-institutes:grid.418306.8
    122 schema:familyName Mori-Anai
    123 schema:givenName Kazumi
    124 rdf:type schema:Person
    125 N1f670cf5912b4e5396b3df2def60c4af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Dipeptidyl-Peptidase IV Inhibitors
    127 rdf:type schema:DefinedTerm
    128 N241579e5d8bd401a9c24e3576d0262f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Glycated Hemoglobin A
    130 rdf:type schema:DefinedTerm
    131 N3449d035938e43159a64c2d2cfe79efc schema:name dimensions_id
    132 schema:value pub.1145402123
    133 rdf:type schema:PropertyValue
    134 N3c33aeb77e5f4f17b3bd042a95571d2e schema:name Springer Nature - SN SciGraph project
    135 rdf:type schema:Organization
    136 N3c956f93b5744a6da73dae4673f8435d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Canagliflozin
    138 rdf:type schema:DefinedTerm
    139 N54f0866afdfb4e47995de2d51e0a727f schema:name pubmed_id
    140 schema:value 35138572
    141 rdf:type schema:PropertyValue
    142 N55a0957764164c7281164e52c27244c5 rdf:first sg:person.01353472360.41
    143 rdf:rest Nf88bd556e4b640d885a484ba73664113
    144 N58c42452a63c4d258addea1fe63baf19 schema:volumeNumber 39
    145 rdf:type schema:PublicationVolume
    146 N60614b922a524492b521eff990862d52 rdf:first sg:person.013066600563.15
    147 rdf:rest Nd384b3ed953941e4b1c7afd77267847a
    148 N619790f77a6e49b58c87d08d57611715 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Pyrazoles
    150 rdf:type schema:DefinedTerm
    151 N691bc87e66c3460385ac1466e3430921 rdf:first sg:person.01004741716.97
    152 rdf:rest Ndab57ea84ef149519488c09753961388
    153 N6aac6b88935642eca330abd6d004e42a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Diabetes Mellitus, Type 2
    155 rdf:type schema:DefinedTerm
    156 N9b1236aa22754913ba4a8e471e72eead schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Body Weight
    158 rdf:type schema:DefinedTerm
    159 N9bdf923e83c14108aaa9fcb9c0111b9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Thiazolidines
    161 rdf:type schema:DefinedTerm
    162 Na21114c514e549fda67bcd30250addbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Blood Glucose
    164 rdf:type schema:DefinedTerm
    165 Na5a70a76cb8d47f48a459041e8ea181e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Humans
    167 rdf:type schema:DefinedTerm
    168 Nbfe09c58865243b59c5ebbe3f1d2f586 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Product Surveillance, Postmarketing
    170 rdf:type schema:DefinedTerm
    171 Nd2a275f05e2442baa7ecf884c23609dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Hypoglycemic Agents
    173 rdf:type schema:DefinedTerm
    174 Nd384b3ed953941e4b1c7afd77267847a rdf:first N098202a1ab5f43d4a45df8eb451feb8f
    175 rdf:rest rdf:nil
    176 Ndab57ea84ef149519488c09753961388 rdf:first sg:person.01335361505.82
    177 rdf:rest Ne5e6944f39484630a4a702b0734d9dd0
    178 Ndedab7c1275b46f1b10b0ac4709db215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Japan
    180 rdf:type schema:DefinedTerm
    181 Ne5e6944f39484630a4a702b0734d9dd0 rdf:first N1cefa83b97eb4b7681f0f66e9bdf6a97
    182 rdf:rest N60614b922a524492b521eff990862d52
    183 Nf88bd556e4b640d885a484ba73664113 rdf:first sg:person.01254012666.61
    184 rdf:rest N691bc87e66c3460385ac1466e3430921
    185 Nff2f7084b98d4bada87c22669dedd38c schema:name doi
    186 schema:value 10.1007/s12325-021-02038-5
    187 rdf:type schema:PropertyValue
    188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    189 schema:name Medical and Health Sciences
    190 rdf:type schema:DefinedTerm
    191 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    192 schema:name Clinical Sciences
    193 rdf:type schema:DefinedTerm
    194 sg:journal.1096634 schema:issn 0741-238X
    195 1865-8652
    196 schema:name Advances in Therapy
    197 schema:publisher Springer Nature
    198 rdf:type schema:Periodical
    199 sg:person.01004741716.97 schema:affiliation grid-institutes:grid.258269.2
    200 schema:familyName Watada
    201 schema:givenName Hirotaka
    202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004741716.97
    203 rdf:type schema:Person
    204 sg:person.01254012666.61 schema:affiliation grid-institutes:grid.258799.8
    205 schema:familyName Inagaki
    206 schema:givenName Nobuya
    207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254012666.61
    208 rdf:type schema:Person
    209 sg:person.013066600563.15 schema:affiliation grid-institutes:grid.418306.8
    210 schema:familyName Iwasaki
    211 schema:givenName Tomohisa
    212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013066600563.15
    213 rdf:type schema:Person
    214 sg:person.01335361505.82 schema:affiliation grid-institutes:grid.418306.8
    215 schema:familyName Sasaki
    216 schema:givenName Kazuyo
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335361505.82
    218 rdf:type schema:Person
    219 sg:person.01353472360.41 schema:affiliation grid-institutes:grid.410813.f
    220 schema:familyName Kadowaki
    221 schema:givenName Takashi
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353472360.41
    223 rdf:type schema:Person
    224 sg:pub.10.1007/s10157-018-1615-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1105570813
    225 https://doi.org/10.1007/s10157-018-1615-x
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1007/s11096-014-9938-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013313922
    228 https://doi.org/10.1007/s11096-014-9938-5
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1007/s11892-015-0602-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026921846
    231 https://doi.org/10.1007/s11892-015-0602-9
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/s12325-019-01189-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1123606886
    234 https://doi.org/10.1007/s12325-019-01189-w
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/s12325-021-01984-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1143544089
    237 https://doi.org/10.1007/s12325-021-01984-4
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s13300-019-0590-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1112634529
    240 https://doi.org/10.1007/s13300-019-0590-x
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1007/s13340-021-00518-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138951105
    243 https://doi.org/10.1007/s13340-021-00518-1
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1007/s40265-019-01086-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113462075
    246 https://doi.org/10.1007/s40265-019-01086-0
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1038/s41574-020-0399-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130824579
    249 https://doi.org/10.1038/s41574-020-0399-8
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1046/j.1525-1497.2002.10905.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019640859
    252 https://doi.org/10.1046/j.1525-1497.2002.10905.x
    253 rdf:type schema:CreativeWork
    254 grid-institutes:grid.258269.2 schema:alternateName Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan
    255 schema:name Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan
    256 rdf:type schema:Organization
    257 grid-institutes:grid.258799.8 schema:alternateName Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
    258 schema:name Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
    259 rdf:type schema:Organization
    260 grid-institutes:grid.410813.f schema:alternateName Toranomon Hospital, Tokyo, Japan
    261 schema:name Toranomon Hospital, Tokyo, Japan
    262 rdf:type schema:Organization
    263 grid-institutes:grid.418306.8 schema:alternateName Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-ku, 541-8505, Osaka, Japan
    264 Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
    265 Quality and Vigilance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
    266 schema:name Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-ku, 541-8505, Osaka, Japan
    267 Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
    268 Quality and Vigilance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
    269 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...